Long COVID and Significant Activity Limitation Among Adults, by Age - United States, June 1-13, 2022, to June 7-19, 2023.


Journal

MMWR. Morbidity and mortality weekly report
ISSN: 1545-861X
Titre abrégé: MMWR Morb Mortal Wkly Rep
Pays: United States
ID NLM: 7802429

Informations de publication

Date de publication:
11 Aug 2023
Historique:
medline: 14 8 2023
pubmed: 10 8 2023
entrez: 10 8 2023
Statut: epublish

Résumé

Long COVID is a condition encompassing a wide range of health problems that emerge, persist, or return following COVID-19. CDC analyzed national repeat cross-sectional Household Pulse Survey data to estimate the prevalence of long COVID and significant related activity limitation among U.S. adults aged ≥18 years by age group. Data from surveys completed between June 1-13, 2022, and June 7-19, 2023, indicated that long COVID prevalence decreased from 7.5% (95% CI = 7.1-7.9) to 6.0% (95% CI = 5.7-6.3) among the overall U.S. adult population, irrespective of history of previous COVID-19, and from 18.9% (95% CI = 17.9-19.8) to 11.0% (95% CI = 10.4-11.6) among U.S. adults reporting previous COVID-19. Among both groups, prevalence decreased from June 1-13, 2022, through January 4-16, 2023, before stabilizing. When stratified by age, only adults aged <60 years experienced significant rates of decline (p<0.01). Among adults reporting previous COVID-19, prevalence decreased among those aged 30-79 years through fall or winter and then stabilized. During June 7-19, 2023, 26.4% (95% CI = 24.0-28.9) of adults with long COVID reported significant activity limitation, the prevalence of which did not change over time. These findings help guide the ongoing COVID-19 prevention efforts and planning for long COVID symptom management and future health care service needs.

Identifiants

pubmed: 37561665
doi: 10.15585/mmwr.mm7232a3
pmc: PMC10415000
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

866-870

Déclaration de conflit d'intérêts

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Douglas Slaughter reports volunteering with the Hood Medicine Initiative during the COVID-19 pandemic. No other potential conflicts of interest were disclosed.

Références

JAMA Netw Open. 2023 Feb 1;6(2):e2256152
pubmed: 36790806
Lancet Infect Dis. 2023 Jul;23(7):776-777
pubmed: 37156258
MMWR Morb Mortal Wkly Rep. 2020 Oct 30;69(43):1584-1590
pubmed: 33119562
BMJ Open. 2023 Jun 7;13(6):e069217
pubmed: 37286327
JAMA Netw Open. 2022 Aug 1;5(8):e2225657
pubmed: 35960522
Int J Epidemiol. 2023 Jun 6;52(3):677-689
pubmed: 37011639
Public Health Rev. 2022 Mar 15;43:1604501
pubmed: 35359614
Prev Med. 2023 Apr;169:107461
pubmed: 36813250

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH